CKD-702 Plus Irinotecan in Gastric Cancer

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Center, Korea
• Treatments: Irinotecan

Criteria

Inclusion Criteria:

• Failed 2 or more lines of chemotherapy

• Tumor overexpressing either MET or EGFR

• Measurable lesion

Exclusion Criteria:

• Prior treatment with anti-MET/EGFR bispecific antibody